Volodymyr Kovalenko

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Dae‐Hyun Yoo, Paweł Hrycaj, Pedro C. Miranda et al. · Annals of the Rheumatic Diseases · 2013 · 650 citations · Full text

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Won Park, Paweł Hrycaj, Volodymyr Kovalenko et al. · Annals of the Rheumatic Diseases · 2013 · 601 citations · Full text

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

Dae‐Hyun Yoo, Chang‐Hee Suh, Seung Cheol Shim et al. · Annals of the Rheumatic Diseases · 2016 · 81 citations · Full text

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis

Won Park, Chang‐Hee Suh, Seung Cheol Shim et al. · BioDrugs · 2017 · 43 citations · Full text

Rheumatoid Disorder, Rheumatology, Medicine +8

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

Dae‐Hyun Yoo, Chang‐Hee Suh, Seung Cheol Shim et al. · BioDrugs · 2017 · 32 citations · Full text